Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
出版年份 2021 全文链接
标题
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
作者
关键词
-
出版物
NATURE MEDICINE
Volume 28, Issue 2, Pages 325-332
出版商
Springer Science and Business Media LLC
发表日期
2021-12-18
DOI
10.1038/s41591-021-01622-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
- (2021) Elise A. Chong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
- (2020) Franck Morschhauser et al. LANCET ONCOLOGY
- Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial
- (2019) Riccardo Bruna et al. HAEMATOLOGICA
- CD19-DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES
- (2019) E.A. Chong et al. HEMATOLOGICAL ONCOLOGY
- Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study
- (2018) Brian K. Link et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
- (2018) Alfredo Rivas-Delgado et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts
- (2018) Clémentine Sarkozy et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials
- (2018) Frederick Lansigan et al. Cancer Medicine
- DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
- (2017) P. Zinzani et al. HEMATOLOGICAL ONCOLOGY
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
- (2016) Gilles Salles et al. HAEMATOLOGICA
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
- (2016) Gilles Salles et al. HAEMATOLOGICA
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- EZH2 mutations are frequent and represent an early event in follicular lymphoma
- (2013) C. Bodor et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started